USCA RIA’s AstraZeneca AZN Stock Holding History

USCA RIA’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,809	Closed	-$308K	–	493
2020 Q3	$308K	Buy	2,809 +100	+4%	+$11.1K	0.02%	362
2020 Q2	$287K	Buy	+2,709	New	+$280K	0.03%	356

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

USCA RIA's AZN Position: Q4 2020 in Review

USCA RIA sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 2,809 shares — an estimated $308K sold.

USCA RIA first reported a position in AZN in Q2 2020 and held it in 2 quarters. The position peaked at $308K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

USCA RIA reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
USCA RIA sold 2,809 AstraZeneca shares in Q4 2020, an estimated $308K.
USCA RIA first reported a position in AstraZeneca in Q2 2020 and held it in 2 quarters.
USCA RIA's AstraZeneca position peaked at $308K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on USCA RIA's 13F filing for Q4 2020, filed 27 Jan 2021.